Yu Siwang, Kong Ah-Ng
Center for Cancer Prevention Research, Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.
Curr Cancer Drug Targets. 2007 Aug;7(5):416-24. doi: 10.2174/156800907781386669.
Prevention is one of the most important and promising strategies to control cancer. Many dietary bioactive compounds, mostly phytochemicals, have been found to decrease the risk of carcinogenesis. Modulating the metabolism and disposition pathways of carcinogens represents one of the major mechanisms by which dietary compounds prevent carcinogenesis. In the present review, the specific molecular targets of dietary compounds within carcinogen metabolism, including various enzymes and transporters and their regulatory signaling pathways, are briefly reviewed. The expression of phase I enzymes, which presumably mostly activate carcinogens, is mainly regulated by xenobiotics sensing nuclear receptors such as AhR, CAR, PXR, and RXR. On the other hand, phase II enzymes catalyze the conjugations of carcinogens and generally are transcriptionally controlled by the Nrf2/ARE signaling pathways. The Nrf2/ARE signaling pathway, which regulates the expression of many detoxifying enzymes, is a major target of dietary compounds. The final excretion of carcinogens and their metabolites is mediated by phase III transporters, which share many regulatory mechanisms with phase I/II enzymes. Indeed, the expression of metabolizing enzymes and transporters is often coordinately regulated. Besides transcriptional regulation, the activities of phase I/II enzymes and phase III transporters could be directly activated or inhibited by dietary compounds. Furthermore, genetic polymorphisms have profound effects on the individual response to dietary compounds. Finally, the effects of cancer prevention and the risk of carcinogenesis are determined by the network composed of known/unknown molecular targets and signaling pathways and its interaction with various xenobiotics, including carcinogens, drugs, and diet. With the rapid advances in the post genomic sciences, it could be possible to decipher this network and better predict the clinical outcomes of cancer prevention by dietary bioactive compounds.
预防是控制癌症最重要且最具前景的策略之一。许多膳食生物活性化合物,主要是植物化学物质,已被发现可降低致癌风险。调节致癌物的代谢和处置途径是膳食化合物预防致癌的主要机制之一。在本综述中,简要回顾了膳食化合物在致癌物代谢中的特定分子靶点,包括各种酶和转运蛋白及其调节信号通路。I相酶的表达可能主要激活致癌物,其主要受异生素感应核受体如芳烃受体(AhR)、组成型雄烷受体(CAR)、孕烷X受体(PXR)和视黄酸X受体(RXR)的调节。另一方面,II相酶催化致癌物的结合反应,通常受核因子E2相关因子2/抗氧化反应元件(Nrf2/ARE)信号通路的转录控制。Nrf2/ARE信号通路调节许多解毒酶的表达,是膳食化合物的主要作用靶点。致癌物及其代谢产物的最终排泄由III相转运蛋白介导,其与I/II相酶具有许多共同的调节机制。实际上,代谢酶和转运蛋白的表达常常受到协同调节。除了转录调节外,膳食化合物可直接激活或抑制I/II相酶和III相转运蛋白的活性。此外,基因多态性对个体对膳食化合物的反应有深远影响。最后,癌症预防效果和致癌风险由由已知/未知分子靶点和信号通路组成的网络及其与各种异生素(包括致癌物、药物和饮食)的相互作用决定。随着后基因组科学的迅速发展,有可能破解这个网络并更好地预测膳食生物活性化合物预防癌症的临床效果。